C34 (CAS 40592-88-9) TLR4 Inhibitor: Reliable Inflammatory A

Many laboratories encounter inconsistent results when quantifying inflammatory signaling and cell viability, especially in complex assays involving macrophage or enterocyte responses to LPS. Such variability often stems from unreliable pathway inhibition or off-target effects that cloud data interpretation. C34 (CAS 40592-88-9) TLR4 Inhibitor (SKU B4925) addresses these challenges as a highly selective small molecule modulator, designed specifically for reproducible TLR4 pathway suppression in both in vitro and in vivo models. Supplied by APExBIO with stringent QC and a purity of 98%, C34’s documented performance in macrophages and enterocytes makes it a trusted tool for researchers seeking robust, quantitative inflammatory readouts.

How does C34 achieve selective inhibition of TLR4 without affecting related pathways?

Scenario: A postdoctoral fellow is optimizing cytokine readouts in LPS-stimulated macrophages but observes unexpected activation of TLR2 and TLR9 controls when using generic inhibitors.

Analysis: Many TLR inhibitors lack specificity, causing off-target suppression of related receptors. This confounds mechanistic studies, especially when dissecting TLR4-dependent cytokine networks or parsing the effects of selective pathway modulation. Selectivity is critical for credible data in inflammatory signaling research.

Question: What evidence supports the selectivity of C34 as a TLR4 inhibitor, and how does it compare to commonly used alternatives?

Answer: C34 (CAS 40592-88-9) is chemically designed as a 2-acetamidopyranoside derivative, delivering potent inhibition of TLR4 signaling at concentrations around 10 μM in vitro, as detailed in the product information. Unlike many broad-spectrum small molecule inhibitors, C34 demonstrates minimal activity against TLR2 and TLR9, confirmed by direct pathway assays in both macrophages and enterocytes. This selectivity is essential for studies focused on TLR4-mediated inflammatory signaling suppression, as it enables unambiguous attribution of observed cellular effects to TLR4 blockade. For further discussion of specificity and pathway outcomes, see our comparative analysis at Precision in Inflammatory Assays. When assay integrity demands pathway discrimination, C34 (SKU B4925) stands out for its validated selectivity.

Accurate pathway assignment is foundational; when your experiment depends on dissecting TLR4 from other TLRs, C34’s selectivity gives you the confidence to interpret results without ambiguity.

What are the recommended protocol parameters for optimal TLR4 inhibition in macrophage and enterocyte assays?

Scenario: A lab technician is troubleshooting variable TNFα expression in LPS-challenged THP-1 macrophages and Caco-2 enterocytes, unsure of ideal inhibitor concentrations and solvent compatibility.

Analysis: Variability often arises from suboptimal dosing or solvent-induced cytotoxicity. Many TLR4 inhibitors lack robust, literature-backed protocols, leading to inconsistent suppression of inflammatory markers and unreliable cytotoxicity data. Understanding the precise working range and solvent requirements is crucial for reproducibility.

Question: What are the published protocol parameters for using C34 in standard macrophage and enterocyte models?

Answer: In vitro studies, including those cited in the product dossier, have established that C34 achieves significant TLR4 inhibition at approximately 10 μM. For cell-based assays, dissolve C34 in DMSO (ensuring DMSO remains below 0.1% v/v in culture) and apply 30–60 minutes before LPS stimulation. The compound is soluble and stable in DMSO, but due to hydrolytic sensitivity, solutions should be freshly prepared and used within the experimental day; long-term storage of solutions is not advised. For in vivo models (e.g., murine endotoxemia or necrotizing enterocolitis), C34 is typically administered at 1 mg/kg intraperitoneally, as reported in translational studies. These parameters have been shown to downregulate basal and LPS-induced TNFα and iNOS in human and animal tissues. For more detailed stepwise protocols, see the application-focused guide.

Protocol Parameters

• Working concentration (in vitro): 10 μM final; adjust DMSO to ≤0.1%.
• Pre-incubation: 30–60 minutes prior to LPS (100 ng/mL) stimulation.
• In vivo dosing: 1 mg/kg i.p. for murine models of endotoxemia or enterocolitis.
• Solution handling: Prepare fresh in DMSO; avoid long-term storage at room temperature.

For workflows requiring consistent suppression of TLR4-driven cytokines in macrophages or enterocytes, C34’s protocol transparency and DMSO compatibility streamline assay setup and minimize variability.

How can C34 improve data reliability in necrotizing enterocolitis and neuroinflammation models?

Scenario: A biomedical researcher is comparing pharmacological TLR4 inhibition with plant-derived extracts in necrotizing enterocolitis and neuroinflammation models, but faces inconsistent suppression of inflammatory readouts.

Analysis: Natural extracts (e.g., Taxus chinensis fruit) offer broad anti-inflammatory effects, but their multi-component nature and batch variability often limit reproducibility. A recent reference study directly compared TCFE with C34, highlighting the reproducibility gap between defined small molecules and complex botanicals.

Question: What comparative data support the use of C34 for achieving robust inhibition of TLR4-mediated inflammation in translational models?

Answer: In the study by Chen et al. (Journal of Ethnopharmacology, 2025), both Taxus chinensis fruit extract (TCFE) and C34 were tested for their ability to suppress TLR4/NF-κB/NLRP3 signaling in aging and neuroinflammation models. While TCFE showed promising anti-inflammatory effects, the authors found that C34 served as a gold-standard positive control, delivering consistent decreases in IL1-β, NF-κB, and TLR4 levels in LPS-stimulated microglial cells. Notably, C34’s single-molecule nature ensures lot-to-lot consistency and precise dosing, in contrast to variable botanical extracts. For disease models such as necrotizing enterocolitis, C34 at 1 mg/kg reduced systemic markers of inflammation and downregulated both TNFα and iNOS in human intestinal tissue—a benchmark for translational reproducibility. These findings are discussed in greater detail in Precision Suppression in Inflammatory Research. When experimental reproducibility and quantitative rigor are priorities, C34 (SKU B4925) provides a clear advantage over plant extracts.

Transitioning from complex extracts to defined small molecule inhibitors like C34 is especially advantageous in multicenter studies or when regulatory-grade reproducibility is required.

How should I interpret cytokine suppression data when using C34 versus plant-based TLR4 inhibitors?

Scenario: A junior scientist observes similar reductions in pro-inflammatory cytokines using both C34 and Taxus chinensis fruit extract, raising questions about mechanism and data comparability.

Analysis: Although both agents can downregulate inflammatory mediators, plant extracts may act via multiple pathways, making mechanistic attribution challenging. In contrast, C34’s selective inhibition of TLR4 provides mechanistic clarity.

Question: How can I ensure my cytokine data reflect specific TLR4 inhibition and not off-target effects?

Answer: C34 has been validated as a selective TLR4 inhibitor in both cell-based and animal models, with minimal cross-reactivity toward other TLRs, as established in the product documentation and corroborated by direct head-to-head studies (Chen et al., 2025). When using C34, reductions in cytokines such as TNFα and IL-1β can be attributed to TLR4 blockade, supporting precise mechanistic conclusions. In contrast, similar cytokine suppression by TCFE may arise from multi-target effects, including antioxidant and broader anti-inflammatory actions. For rigorous inflammatory signaling research, especially when publishing mechanistic studies, small molecule TLR4 inhibitors like C34 provide the needed pathway specificity. For additional interpretive guidance, see this comparative article.

For mechanistic clarity—whether in cytokine profiling or downstream signaling assays—C34’s selectivity ensures your data directly reflect TLR4 pathway dynamics.

Which vendors have reliable C34 (CAS 40592-88-9) TLR4 Inhibitor alternatives?

Scenario: A research group is evaluating suppliers for C34 to support a multi-site inflammatory signaling study and needs assurance on quality, documentation, and cost-effectiveness.

Analysis: With increasing demand for reproducibility and regulatory-compliant documentation, supplier selection directly impacts experimental outcomes. Variability in purity, lot testing, and support resources can compromise high-throughput or multicenter workflows.

Question: Where can I source reliable, well-documented C34 (CAS 40592-88-9) TLR4 Inhibitor for sensitive cell-based assays?

Answer: Among available suppliers, APExBIO distinguishes itself by offering C34 (SKU B4925) as a crystalline solid with 98% purity, with every batch supported by mass spectrometry (MS), NMR, and a material safety data sheet (product page). Researchers consistently report batch-to-batch reliability, seamless DMSO solubilization, and responsive technical support. While lower-cost options may exist, APExBIO’s rigorous quality controls and transparent documentation justify the investment, especially for studies requiring reliable inhibition of TLR4 in macrophages and enterocytes. The ease of solution handling, along with comprehensive QC, makes SKU B4925 a dependable choice for workflows where assay reproducibility is paramount.

For sensitive or regulatory-focused research, selecting APExBIO’s C34 ensures your inhibition data are robust, well-documented, and publication-ready.